Form 4: SOPHiA GENETICS CEO Executes Tax-Related Share Sale
Statement of Changes in Beneficial Ownership
CEO Jurgi Camblong sold 60,602 shares of SOPHiA GENETICS to cover tax obligations related to RSU vesting.
Summary
- CEO Jurgi Camblong sold a total of 60,602 ordinary shares of SOPHiA GENETICS (SOPH) on April 14 and April 15, 2026.
- The sales were executed to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs) on April 2 and 3, 2026.
- The transactions were conducted under a pre-established Rule 10b5-1(c) trading plan, indicating they were non-discretionary.
- Following these transactions, the CEO retains beneficial ownership of 3,646,967 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a change in business fundamentals.
Positives
- The sale was non-discretionary and executed pursuant to a pre-established Rule 10b5-1(c) trading plan, mitigating concerns regarding insider sentiment.
- The transaction was strictly for tax compliance purposes rather than a signal of lack of confidence in the company.
Negatives
- The reduction in the CEO's direct shareholding, though minor relative to total holdings, represents a decrease in direct equity stake.
Risks
- Reliance on equity-based compensation and subsequent tax-related sales can lead to periodic selling pressure on the stock.
Future Outlook
No forward-looking guidance or operational outlook was provided in this filing.
Management Comments
- The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
Industry Context
StockSavvy.ai notes that tax-related sell-downs by executives in the biotech sector are standard practice during RSU vesting cycles and generally do not reflect changes in corporate strategy or outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to manage tax liabilities while avoiding potential insider trading allegations.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and non-discretionary.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 04/02/2026 | Vesting date of restricted stock units. |
| 04/03/2026 | Vesting date of restricted stock units. |
| 04/14/2026 | First date of share sales. |
| 04/15/2026 | Second date of share sales. |
| 04/16/2026 | Filing date of the Form 4. |
Keywords
SOPHiA GENETICS, SOPH, Insider Trading, Form 4, Jurgi Camblong, Biotech, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.